- 2005 Paul C. Aebersold Award for Outstanding Achievement -
MORRIS PLAINS, N.J., June 20 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU), a leading biopharmaceutical company focused on developing
monoclonal antibodies, announced today that its founder and Chairman of the
Board of Directors, David M. Goldenberg, Sc.D., M.D., was the recipient of the
2005 Paul C. Aebersold Award at the 52nd Annual Meeting of the Society of
Nuclear Medicine in Toronto, Canada.
"I am humbled to be among these giants of nuclear medicine. I am
especially grateful to the Society for recognizing my contributions to basic
science applied to nuclear medicine," commented Dr. Goldenberg.
In awarding Dr. Goldenberg its highest honor, the Society of Nuclear
Medicine recognized his contributions to the basic science of nuclear medicine
by his pioneering work in the development of radiolabeled antibodies for
various applications in the detection, diagnosis, and therapy of solid tumors,
such as colorectal, pancreatic, lung, breast, and ovarian cancers, as well as
certain hematologic cancers, such as lymphoma and multiple myeloma.
About Dr. David M. Goldenberg
Dr. David M. Goldenberg is the founder of Immunomedics and is currently
the Chairman of its Board of Directors. He also serves as Chairman of the
Board of Directors of IBC Pharmaceuticals, Inc., a subsidiary of Immunomedics.
Dr. Goldenberg is a graduate of the University of Chicago College and Division
of Biological Sciences (B.S.), the University of Erlangen-Nuremberg (Germany)
Faculty of Natural Sciences (Sc.D.), and the University of Heidelberg
(Germany) School of Medicine (M.D.). He has written or co-authored more than
1,500 journal articles, book chapters and abstracts on cancer research,
detection and treatment, and has researched and written extensively in the
area of radioimmunodetection and radioimmunotherapy using radiolabeled
antibodies. In addition to his position with Immunomedics, Dr. Goldenberg is
President of the Center for Molecular Medicine and Immunology ("CMMI"), an
independent non-profit research center, and its clinical unit, the Garden
State Cancer Center. In 1985 and again in 1992, Dr. Goldenberg received an
"Outstanding Investigator Grant" award from the National Cancer Institute for
his work in radioimmunodetection, and in 1986 he received the New Jersey Pride
Award in Science and Technology. Dr. Goldenberg was honored as the ninth Herz
Lecturer of the Tel Aviv University Faculty of Life Sciences. In addition, he
received the 1991 Mayneord 3M Award and Lectureship of the British Institute
of Radiology, and in 2002, the Elis Bervin Lectureship and Medal from the
Swedish Medical Society and the Swedish Oncology Society for his contributions
to the development of radiolabeled monoclonal antibodies used in the imaging
and treatment of cancer. The International Society for Oncodevelopmental
Biology and Medicine also named Dr. Goldenberg the co-recipient of its 1994
Abbott Award.
About Immunomedics
Immunomedics is a New Jersey-based biopharmaceutical company focused on
the development of monoclonal antibody-based products for the targeted
treatment of cancer, autoimmune and other serious diseases. We have developed
a number of advanced proprietary technologies that allow us to create
humanized antibodies that can be used either alone in unlabeled or "naked"
form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in
each case to create highly targeted agents. Using these technologies, we have
built a pipeline of therapeutic product candidates that utilize several
different mechanisms of action. Our lead product candidate, epratuzumab, is
currently in two pivotal Phase III trials, for the treatment of patients with
moderate and severe lupus. At present, there is no cure for lupus and no new
lupus treatment drug has been approved in the U.S. in the last 40 years. We
believe that our portfolio of intellectual property, which includes
approximately 90 issued patents in the United States, and more than 250 other
issued patents worldwide, protects its product candidates and technologies.
Visit the Company's web site at http://www.immunomedics.com.
This release, in addition to historical information, may contain forward-
looking statements made pursuant to the Private Securities Litigation Reform
Act of 1995. Such statements, including statements regarding clinical trials,
out-licensing arrangements, and capital raising activities, involve
significant risks and uncertainties and actual results could differ materially
from those expressed or implied herein. Factors that could cause such
differences include, but are not limited to, risks associated with new product
development (including clinical trials outcome and regulatory
requirements/actions), competitive risks to marketed products and availability
of financing and other sources of capital, as well as the risks discussed in
the Company's Annual Report on Form 10-K for the fiscal year ended June 30,
2004. The Company is not under any obligation, and the Company expressly
disclaims any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise.
For More Information:
Dr. Chau Cheng
Associate Director, Investor Relations & Business Analysis,
(973)605-8200 extension 123
ccheng@immunomedics.com
SOURCE Immunomedics, Inc.
 back to top
Related links:
http://www.Immunomedics.com
Company News On-Call:
http://www.prnewswire.com/comp/113121.html
CONTACT:
Dr. Chau Cheng, Associate Director, Investor
Relations & Business Analysis, +1-973-605-8200 ext. 123,
ccheng@immunomedics.com
|
